ATLAS & FLAIR Phase 3 Results In High Level Viral Suppression With Injection Therapy

Home / NTIDC News / ATLAS & FLAIR Phase 3 Results In High Level Viral Suppression With Injection Therapy
ATLAS & FLAIR Phase 3 Results In High Level Viral Suppression With Injection Therapy

ATLAS & FLAIR Phase 3 Results In High Level Viral Suppression With Injection Therapy

At the 2019 Conference on Retroviruses and Opportunistic Infections (CROI), the ATLAS and FLAIR study presented the Phase 3 findings of the Dual Therapy Cabotegravir and Rilpivirine (CAB+RVP) Long-Acting Injection trial. The Flair study enrolled Naïve subjects and compared a daily pill containing dolutegravir, abacavir, and lamivudine (Triumeq) to the Long-Acting Injection. The Atlas study compared a switch to monthly CAB+RVP versus subjects continuing their current effective antiretroviral regimen.

In the ATLAS study, the duration of the study was 96 weeks and it showed high levels of viral suppression in participants. Moreover, 97% of participants stated they preferred injections compared to oral combination therapy.

In the FLAIR study, participants were younger compared to the ATLAS study with a median age of 34. The study also showed high level of viral suppression and met criteria for non-inferiority to its comparator Triumeq. Also, 91% of participants stated they preferred injection therapy compared to oral therapy.

The ATLAS and FLAIR study showed positive results of high levels of virus suppression for participants who seek injection therapy compared to oral therapy.

NTIDC Research department is participating in Flair and Atlas trials with Dr. Chris Bettacchi as the principle Investigator.

Please click the link to review the Phase 3 Results: http://www.thebodypro.com/content/81647/cabotegravir-rilpivirine-long-acting-atlas-flair.html?ic=tbphnews

 

References:

  1. Swindells S et al. Long-acting cabotegravir + rilpivirine as maintenance therapy: atlas week 48 results. CROI 4 – 7 March 2019, Seattle. Oral abstract 139.
  2. Orkin C et al. LONG-ACTING CABOTEGRAVIR+RILPIVIRINE FOR HIV maintenance: FLAIR week 48 RESULTS. CROI 4 – 7 March 2019, Seattle. Late breaker oral abstract 140LB.
  3. Collins S. Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies. TheBodyPROcom 2019. http://www.thebodypro.com/content/81647/cabotegravir-rilpivirine-long-acting-atlas-flair.html?ic=tbphnews (accessed April 18, 2019).
North Texas Infectious Diseases